Discussion

The COVID-19 public health crisis affects everyone in our global community. Crucial questions about how SARS-CoV-2 affects our immune system must be answered, and quickly.

Investigators need fast, reliable cytometric assays to completely capture immune cell population changes at different stages of infection and in response to treatments. Finding an easy end-to-end workflow requiring no special expertise can be a challenge.

The Maxpar® Direct™ Immune Profiling System, designed for use on CyTOF® systems, provides the ideal solution:

A 30-marker backbone panel in a dry, single-tube format
Room to add at least 14 more antibodies of your choice
Capable of processing fresh whole blood samples or PBMCs
Enabling automatic enumeration of 37 immune cell populations in 5 minutes using Maxpar Pathsetter™ analysis software
We invite you to hear Roberto Spada, Senior Business Development Manager at Fluidigm, describe how researchers are already using both suspension mass cytometry and Imaging Mass Cytometry™ (IMC™) to monitor the immune response in COVID-19 therapeutic research. He will also provide details about the Maxpar Direct Immune Profiling System.